Company Focus
Icon
Latest Icon News
Pharmaceutical
As the world’s leading cancer research professionals arrived at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona on Friday, they were given a reminder of some of the remaining challenges that lie ahead in their field. 13 September 2024
Related News
Insights
Company Spotlight
A biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates.
Latest News & Features of interest to Icon
Biotechnology
French biotech Igyxos Biotherapeutics today announced the appointments of Florent Ferré as chief executive and Dr Elke Bestel as chief medical officer to reinforce its management team and executive committee. 19 December 2024
Biotechnology
December 19, 2024
The US Food and Drug Administration (FDA) approved Ryoncil (remestemcel-L-rknd), from Australia’s Mesoblast, whose shares rocketed 54% to A$3.05 on the news. 19 December 2024
Pharmaceutical
Japanese firms Nxera Pharma- formerly known as Sosei Group or Sosei Heptares- and Shionogi have announced that Quviviq (daridorexant) 25mg and 50 mg has been launched and is now available in the Asian country as a new treatment for adults with insomnia. 19 December 2024
Biotechnology
New York pharma giant Bristol Myers Squibb is getting into Alzheimer’s in a big way, snapping up global rights to an antibody program from BioArctic. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
US pharma giant Merck & Co and Chinese biopharma Hansoh Pharma have entered into an exclusive global license agreement for HS-10535, an investigational pre-clinical oral small molecule GLP-1 receptor agonist (RA). 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Pharmaceutical
Sweden-based biotech Hansa Biopharma has released promising full results from a Phase II study evaluating imlifidase, its IgG-cleaving enzyme, in severe Guillain-Barré syndrome (GBS). 18 December 2024
Biotechnology
Eli Lilly has announced that China’s National Medical Products Administration has approved Kisunla (donanemab-azbt) for certain adults with early Alzheimer’s disease. 18 December 2024
Biotechnology
US healthcare giant Johnson & Johnson has announced the submission of a Type II variation application to the European Medicines Agency (EMA). 18 December 2024
Latest In Brief for Icon
Biotechnology
The Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) for the treatment of early Alzheimer’s disease (AD). 5 December 2024
Latest Relevant Ones To Watch News
Privately-held immunotherapy company Inmagene Biopharmaceuticals is taking over Ikena Oncology in a reverse merger deal, forming a new company, InmageneBio. 27 December 2024
19 December 2024
17 December 2024
16 December 2024
16 December 2024
13 December 2024
12 December 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze